Repro Med Shares Outstanding vs. Current Valuation
| KRMD Stock | USD 4.04 0.11 2.80% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.46 | 0.5859 |
|
|
For Repro Med profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Repro Med to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Repro Med Systems utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Repro Med's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Repro Med Systems over time as well as its relative position and ranking within its peers.
Repro |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repro Med. If investors know Repro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repro Med listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (0.26) | Revenue Per Share 0.674 | Quarterly Revenue Growth 0.215 | Return On Assets (0.14) |
The market value of Repro Med Systems is measured differently than its book value, which is the value of Repro that is recorded on the company's balance sheet. Investors also form their own opinion of Repro Med's value that differs from its market value or its book value, called intrinsic value, which is Repro Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repro Med's market value can be influenced by many factors that don't directly affect Repro Med's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repro Med's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repro Med is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repro Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Repro Med Systems Current Valuation vs. Shares Outstanding Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Repro Med's current stock value. Our valuation model uses many indicators to compare Repro Med value to that of its competitors to determine the firm's financial worth. Repro Med Systems is rated fourth overall in shares outstanding category among its peers. It is rated below average in current valuation category among its peers reporting about 3.99 of Current Valuation per Shares Outstanding. Comparative valuation analysis is a catch-all technique that is used if you cannot value Repro Med by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Repro Current Valuation vs. Shares Outstanding
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Repro Med |
| = | 45.84 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Repro Med |
| = | 182.91 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Repro Current Valuation vs Competition
Repro Med Systems is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 41.46 Billion. Repro Med adds roughly 182.91 Million in current valuation claiming only tiny portion of equities under Health Care industry.
Repro Med Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Repro Med, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Repro Med will eventually generate negative long term returns. The profitability progress is the general direction of Repro Med's change in net profit over the period of time. It can combine multiple indicators of Repro Med, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -10.3 M | -9.8 M | |
| Income Before Tax | -9.8 M | -9.3 M | |
| Total Other Income Expense Net | 496.4 K | 521.2 K | |
| Net Loss | -13.7 M | -13.1 M | |
| Income Tax Expense | 4 M | 4.2 M | |
| Interest Income | 561.3 K | 589.4 K | |
| Net Loss | -13.7 M | -13.1 M | |
| Net Loss | -7.8 M | -7.4 M | |
| Net Interest Income | 561.3 K | 589.4 K | |
| Non Operating Income Net Other | 121.6 K | 115.5 K | |
| Change To Netincome | 1.2 M | 882.4 K | |
| Net Loss | (0.30) | (0.29) | |
| Income Quality | 0.36 | 0.37 | |
| Net Income Per E B T | 1.41 | 1.01 |
Repro Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Repro Med. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Repro Med position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Repro Med's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Repro Med without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
| All Next | Launch Module |
Use Investing Themes to Complement your Repro Med position
In addition to having Repro Med in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Crypto And Gold Thematic Idea Now
Crypto And Gold
Assets that cancel away each other volatility by providing diversification into gold investment combined with digital assets. The Crypto And Gold theme has 54 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Crypto And Gold Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
To fully project Repro Med's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Repro Med Systems at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Repro Med's income statement, its balance sheet, and the statement of cash flows.